Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis
{{output}}
Background: KL130008, a novel selective JAK1/JAK2 inhibitor demonstrated acceptable safety and tolerability in Phase I studies involving healthy volunteers. This proof-of-concept trial aimed to characterize the pharmacokinetic/ph... ...
